Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
6.10
+0.31 (5.35%)
At close: Dec 20, 2024, 4:00 PM
6.25
+0.15 (2.46%)
After-hours: Dec 20, 2024, 5:43 PM EST
Olema Pharmaceuticals Employees
Olema Pharmaceuticals had 74 employees as of December 31, 2023. The number of employees decreased by 12 or -13.95% compared to the previous year.
Employees
74
Change (1Y)
-12
Growth (1Y)
-13.95%
Revenue / Employee
n/a
Profits / Employee
-$1,657,824
Market Cap
349.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 74 | -12 | -13.95% |
| Dec 31, 2022 | 86 | 12 | 16.22% |
| Dec 31, 2021 | 74 | 37 | 100.00% |
| Dec 31, 2020 | 37 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AngioDynamics | 748 |
| Sage Therapeutics | 487 |
| Kamada | 378 |
| Sana Biotechnology | 328 |
| NeuroPace | 171 |
| Absci | 155 |
| Design Therapeutics | 58 |
| GH Research | 49 |
OLMA News
- 3 days ago - Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
- 11 days ago - Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 12 days ago - Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor - GlobeNewsWire
- 17 days ago - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 5 weeks ago - Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 - GlobeNewsWire